Press coverage about BioSpecifics Technologies (NASDAQ:BSTC) has trended somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. BioSpecifics Technologies earned a news sentiment score of 0.20 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.1170688799353 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

These are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:

Several equities research analysts have commented on BSTC shares. BidaskClub cut shares of BioSpecifics Technologies from a “sell” rating to a “strong sell” rating in a research report on Friday, August 18th. Zacks Investment Research upgraded shares of BioSpecifics Technologies from a “sell” rating to a “hold” rating in a research report on Tuesday, October 10th. HC Wainwright reiterated a “buy” rating on shares of BioSpecifics Technologies in a research report on Monday. Finally, dropped their price target on shares of BioSpecifics Technologies from $72.00 to $65.00 and set a “buy” rating on the stock in a research report on Wednesday, November 15th.

Shares of BioSpecifics Technologies (NASDAQ BSTC) opened at $44.14 on Thursday. BioSpecifics Technologies has a 1 year low of $41.95 and a 1 year high of $58.79. The company has a market cap of $310.58, a PE ratio of 27.17 and a beta of 1.58.

BioSpecifics Technologies (NASDAQ:BSTC) last issued its quarterly earnings results on Friday, November 10th. The biopharmaceutical company reported $0.37 EPS for the quarter, topping the consensus estimate of $0.36 by $0.01. BioSpecifics Technologies had a net margin of 42.40% and a return on equity of 19.11%. The firm had revenue of $6.52 million for the quarter, compared to analysts’ expectations of $6.59 million. sell-side analysts expect that BioSpecifics Technologies will post 1.57 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “BioSpecifics Technologies (BSTC) Receiving Somewhat Positive News Coverage, Accern Reports” was reported by Daily Political and is the property of of Daily Political. If you are reading this report on another website, it was copied illegally and reposted in violation of US and international copyright legislation. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/12/14/biospecifics-technologies-bstc-receiving-somewhat-positive-news-coverage-accern-reports.html.

About BioSpecifics Technologies

BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development.

Insider Buying and Selling by Quarter for BioSpecifics Technologies (NASDAQ:BSTC)

Receive News & Ratings for BioSpecifics Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies and related companies with MarketBeat.com's FREE daily email newsletter.